SPHBio

SPH Biopharmaceutical (SPHBio) is a clinical-stage biotechnology company and a core subsidiary of Shanghai Pharmaceuticals Holding Co., Ltd., one of China's largest pharmaceutical groups. The company is dedicated to the research, development, and commercialization of innovative biological drugs, including monoclonal antibodies, antibody-drug conjugates (ADCs), and recombinant proteins. Its pipeline primarily targets high-unmet-need areas in oncology, autoimmune disorders, and metabolic diseases. SPHBio leverages an integrated platform that spans from early-stage discovery to large-scale GMP manufacturing. By combining internal R&D with global strategic collaborations, the company aims to deliver advanced therapeutic solutions to the international market. The company operates state-of-the-art facilities in Shanghai's Zhangjiang Hi-Tech Park, positioning itself as a leader in China's biopharmaceutical innovation landscape.